THYROID ASSOCIATED OPHTHALMOPATHIES
Clinical trials for THYROID ASSOCIATED OPHTHALMOPATHIES explained in plain language.
Never miss a new study
Get alerted when new THYROID ASSOCIATED OPHTHALMOPATHIES trials appear
Sign up with your email to follow new studies for THYROID ASSOCIATED OPHTHALMOPATHIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for thyroid eye disease: drug targets bulging eyes and double vision
Disease control Recruiting nowThis study tests a drug called IBI311 in 50 people with inactive moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and double vision. IBI311 blocks a protein that drives inflammation and tissue growth around the eyes. The goal is to see if it improve…
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 17, 2026 05:21 UTC
-
New hope for bulging eyes: drug trial targets thyroid disease
Disease control Recruiting nowThis study tests a new drug called MHB018A for people with active moderate-to-severe thyroid eye disease, a condition that causes eye bulging and discomfort. About 108 adults aged 18-75 will receive either the drug or a placebo every 4 weeks for 6 months. The main goal is to see …
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated May 17, 2026 05:20 UTC
-
New drug combo shows promise for thyroid eye disease sufferers
Disease control Recruiting nowThis study tests a new drug called IBI311 against standard hormone therapy for people with active moderate to severe thyroid eye disease (TAO). TAO is an autoimmune condition that can cause bulging eyes, double vision, and even blindness. The trial will enroll 64 participants to …
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 17, 2026 05:18 UTC
-
New hope for thyroid eye disease: antibody therapy after steroids shows promise
Disease control Recruiting nowThis study tests a drug called tetuzumab (IBI311) in people with moderate to severe thyroid eye disease (TAO) who did not get enough help from steroids. The drug blocks a protein that fuels inflammation and tissue swelling behind the eyes. About 96 adults will receive the treatme…
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
Eye-Tracking tech reveals hidden impact of thyroid eye disease
Knowledge-focused Recruiting nowThis study uses a non-invasive eye-tracking device to measure how Thyroid-Associated Ophthalmopathy (TAO) affects eye movement and visual attention. Researchers will compare 100 participants—both patients with TAO and healthy volunteers—as they watch images on a screen. The goal …
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Sponsor: Shanghai Changzheng Hospital • Aim: Knowledge-focused
Last updated May 14, 2026 12:05 UTC